 Treatment anemia chronic renal failure subcutaneous recombinant human erythropoietin PURPOSE purpose study efficacy recombinant human erythropoietin rHuEPO times/week patients chronic renal failure anemia predialysis PATIENTS METHODS Eleven patients predialysis chronic renal failure double-blind placebo-controlled study erythropoietin weeks patients rHuEPO mu/kg body times/week placebo weeks placebo patients rHuEPO dose mu/kg times/week target hematocrit study blood pressure blood work hemoglobin hematocrit reticulocyte count iron profile determinations RESULTS weeks hematocrit treated group placebo group baseline hematocrit weeks weeks rHuEPO therapy hematocrit prior placebo group versus baseline significant change biochemical parameters Mean blood pressure values comparable treatment iron supplementation patients rate progression renal failure hematocrit rHuEPO CONCLUSIONS rHuEPO effective safe therapy patients chronic renal failure anemic dialysis